Advertisement

Topics

Aclaris Therapeutics, Inc. Company Profile

06:58 EDT 20th June 2018 | BioPortfolio

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. Visit www.aclaristx.com for more information.


News Articles [812 Associated News Articles listed on BioPortfolio]

Wart Medication Meets Primary And Secondary Endpoints In Phase 2 Trial

NewsIf approved, the A-101 45% Topical Solution developed by Aclaris Therapeutics would be the first FDA approved treatment for common warts, which affect more than 22 million Americans.

Aclaris, Cipher to market raised seborrheic keratoses therapy in Canada

Cipher Pharmaceuticals acquired the Canadian rights to commercialize Aclaris Therapeutics' A-101 40% topical solution, which  -More- 

Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 8:00 AM Ea...

Aclaris launches raised seborrheic keratoses therapy

Aclaris Therapeutics launched FDA-approved Eskata, or hydrogen peroxide, as a topical therapy for raised seborrheic keratoses -More- 

Aclaris Therapeutics to Present at the 2018 American Hair Research Summit

WAYNE, Pa., May 11, 2018 (GLOBE NEWSWIRE) -- Paul Changelian, Ph.D., Vice President, Biology, Aclaris Therapeutics, Inc. (NASDAQ:ACRS), will speak at the 2018 American Hair Research Summit on “Pr...

Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine

WAYNE, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing i...

Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

MALVERN, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase ...

Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting

WAYNE, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innova...

PubMed Articles [426 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1236 Associated Companies listed on BioPortfolio]

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel de...

Aclaris Therapeutics Inc.

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel de...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Aclaris Therapeutics, Inc." on BioPortfolio

We have published hundreds of Aclaris Therapeutics, Inc. news stories on BioPortfolio along with dozens of Aclaris Therapeutics, Inc. Clinical Trials and PubMed Articles about Aclaris Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aclaris Therapeutics, Inc. Companies in our database. You can also find out about relevant Aclaris Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record